Skip to main content
. Author manuscript; available in PMC: 2022 Oct 20.
Published in final edited form as: Toxicol Appl Pharmacol. 2022 Aug 9;452:116193. doi: 10.1016/j.taap.2022.116193

Fig. 3.

Fig. 3.

AsIII impairs the DNA binding activity of GATA-2. Primary mouse bone marrow HPCs stimulated with EPO and SCF to undergo erythroid lineage commitment and differentiation were treated with 0 or 500 nM AsIII for 48 h. Following AsIII exposure, GATA-2 DNA binding activity was measured by ChIP-qPCR at four known GATA-2 regulatory sites: (A) −2 kb upstream of GATA-2 promoter (−2.8 kb), (B) Pbx1, (C) Rhag1, and (D) Mllt3. Data are expressed as mean ± SD, n = 12/group, *p < 0.05, **p < 0.01 in Student’s t-test compared to untreated control.